Literature DB >> 17635610

Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment.

Konrad A Bode1, Kate Schroder, David A Hume, Timothy Ravasi, Klaus Heeg, Matthew J Sweet, Alexander H Dalpke.   

Abstract

Post-translational modifications of histone proteins are major mechanisms that modify chromatin structure and regulate gene expression in eukaryotes. Activation of histone acetyltransferases or inhibition of histone deacetylases (HDACs) is generally believed to allow chromatin to assume a more open state, permitting transcriptional activity. We report here the surprising observation that treatment of murine dendritic cells with the HDAC inhibitors trichostatin A (TSA) or suberoylanilide hydroxamic acid (SAHA) in non-apoptotic concentrations strongly inhibited induction of both interleukin-12 protein p40 (IL-12p40) mRNA and protein upon stimulation of Toll-like receptors (TLRs). Moreover, TLR-mediated up-regulation of costimulatory molecules was also inhibited. Up-regulation of tumour necrosis factor-alpha mRNA and protein in response to TLR agonists was only affected upon prolonged exposure to HDAC inhibitors and regulation of IL-1 beta was not affected. Similar effects were apparent in murine and human macrophages. Regarding the mode of action, HDAC inhibition increased the acetylation status at the IL-12p40 locus. Nevertheless, IL-12p40 chromatin remodelling, binding of Rel-A and IRF1 to the IL-12p40 promoter and transcriptional activation were abrogated. In contrast, HDAC inhibitors had no effects on upstream nuclear factor-kappaB and mitogen-activated protein kinase activation. Thus HDACs positively regulate the expression of a subset of cytokine genes by enabling transcription factor recruitment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17635610      PMCID: PMC2266046          DOI: 10.1111/j.1365-2567.2007.02678.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  52 in total

1.  Interleukin-12 p40 promoter activity is regulated by the reversible acetylation mediated by HDAC1 and p300.

Authors:  Jun Lu; Haijing Sun; Xiuli Wang; Chunyan Liu; Xin Xu; Fen Li; Baiqu Huang
Journal:  Cytokine       Date:  2005-07-07       Impact factor: 3.861

2.  Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2.

Authors:  Kentaro Yamaguchi; Agnieszka Lantowski; Andrew J Dannenberg; Kotha Subbaramaiah
Journal:  J Biol Chem       Date:  2005-07-01       Impact factor: 5.157

3.  The nuclear factor-kappaB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter.

Authors:  W Vanden Berghe; K De Bosscher; E Boone; S Plaisance; G Haegeman
Journal:  J Biol Chem       Date:  1999-11-05       Impact factor: 5.157

4.  Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells.

Authors:  Y B Kim; S W Ki; M Yoshida; S Horinouchi
Journal:  J Antibiot (Tokyo)       Date:  2000-10       Impact factor: 2.649

5.  Nucleosome remodeling at the IL-12 p40 promoter is a TLR-dependent, Rel-independent event.

Authors:  A S Weinmann; D M Mitchell; S Sanjabi; M N Bradley; A Hoffmann; H C Liou; S T Smale
Journal:  Nat Immunol       Date:  2001-01       Impact factor: 25.606

6.  Duration of nuclear NF-kappaB action regulated by reversible acetylation.

Authors:  W Fischle; E Verdin; W C Greene
Journal:  Science       Date:  2001-08-31       Impact factor: 47.728

7.  MHC class II transactivator inhibits IL-4 gene transcription by competing with NF-AT to bind the coactivator CREB binding protein (CBP)/p300.

Authors:  T J Sisk; T Gourley; S Roys; C H Chang
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

8.  Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines.

Authors:  Y Hoshikawa; H J Kwon; M Yoshida; S Horinouchi; T Beppu
Journal:  Exp Cell Res       Date:  1994-09       Impact factor: 3.905

9.  Toll-like receptors differentially induce nucleosome remodelling at the IL-12p40 promoter.

Authors:  Inka Albrecht; Thomas Tapmeier; Stefan Zimmermann; Markus Frey; Klaus Heeg; Alexander Dalpke
Journal:  EMBO Rep       Date:  2004-01-23       Impact factor: 8.807

10.  Activation of the mouse cytokeratin A (endo A) gene in teratocarcinoma F9 cells by the histone deacetylase inhibitor Trichostatin A.

Authors:  T Miyashita; H Yamamoto; Y Nishimune; M Nozaki; T Morita; A Matsushiro
Journal:  FEBS Lett       Date:  1994-10-17       Impact factor: 4.124

View more
  67 in total

Review 1.  Histone/protein deacetylases and T-cell immune responses.

Authors:  Tatiana Akimova; Ulf H Beier; Yujie Liu; Liqing Wang; Wayne W Hancock
Journal:  Blood       Date:  2012-01-12       Impact factor: 22.113

Review 2.  TLR8: an innate immune receptor in brain, neurons and axons.

Authors:  Yinghua Ma; Robin L Haynes; Richard L Sidman; Timothy Vartanian
Journal:  Cell Cycle       Date:  2007-09-04       Impact factor: 4.534

Review 3.  Epigenetic mechanisms in diabetic vascular complications.

Authors:  Marpadga A Reddy; Rama Natarajan
Journal:  Cardiovasc Res       Date:  2011-01-25       Impact factor: 10.787

4.  HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats.

Authors:  Jeffrey P Cardinale; Srinivas Sriramula; Romain Pariaut; Anuradha Guggilam; Nithya Mariappan; Carrie M Elks; Joseph Francis
Journal:  Hypertension       Date:  2010-08-02       Impact factor: 10.190

5.  Regulation of Nitrogen Mustard-Induced Lung Macrophage Activation by Valproic Acid, a Histone Deacetylase Inhibitor.

Authors:  Alessandro Venosa; James G Gow; LeRoy Hall; Rama Malaviya; Andrew J Gow; Jeffrey D Laskin; Debra L Laskin
Journal:  Toxicol Sci       Date:  2017-05-01       Impact factor: 4.849

6.  The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients.

Authors:  Michael J Kelly-Sell; Youn H Kim; Suzanne Straus; Bernice Benoit; Cameron Harrison; Katherine Sutherland; Randall Armstrong; Wen-Kai Weng; Louise C Showe; Maria Wysocka; Alain H Rook
Journal:  Am J Hematol       Date:  2012-02-24       Impact factor: 10.047

7.  Down-regulation of miR-301a suppresses pro-inflammatory cytokines in Toll-like receptor-triggered macrophages.

Authors:  Lisong Huang; Yin Liu; Liqiu Wang; Ruifeng Chen; Wei Ge; Zhusen Lin; Yun Zhang; Shuyuan Liu; Yi Shan; Qingxian Lin; Minghong Jiang
Journal:  Immunology       Date:  2013-11       Impact factor: 7.397

8.  Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice.

Authors:  Pavan Reddy; Yaping Sun; Tomomi Toubai; Raimon Duran-Struuck; Shawn G Clouthier; Elizabeth Weisiger; Yoshinobu Maeda; Isao Tawara; Oleg Krijanovski; Erin Gatza; Chen Liu; Chelsea Malter; Paolo Mascagni; Charles A Dinarello; James L M Ferrara
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

9.  Aging-dependent upregulation of IL-23p19 gene expression in dendritic cells is associated with differential transcription factor binding and histone modifications.

Authors:  Rabab El Mezayen; Mohamed El Gazzar; Rebecca Myer; Kevin P High
Journal:  Aging Cell       Date:  2009-07-13       Impact factor: 9.304

10.  Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo.

Authors:  Daniela Bosisio; Marisa Vulcano; Annalisa Del Prete; Marina Sironi; Valentina Salvi; Laura Salogni; Elena Riboldi; Flavio Leoni; Charles A Dinarello; Giampiero Girolomoni; Silvano Sozzani
Journal:  J Leukoc Biol       Date:  2008-09-09       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.